Publication:
Childhood immune thrombocytopenia: Long-term follow-up data evaluated by the criteria of the international working group on immune thrombocytopenic purpura

dc.contributor.buuauthorSezgin, Melike Evim
dc.contributor.buuauthorBaytan, Birol
dc.contributor.buuauthorGüneş, Adalet Meral
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentPediatrik Hematoloji Ana Bilim Dalı
dc.contributor.researcheridAAH-1452-2021
dc.contributor.scopusid36667380300
dc.contributor.scopusid6506622162
dc.contributor.scopusid24072843300
dc.date.accessioned2023-06-21T06:29:38Z
dc.date.available2023-06-21T06:29:38Z
dc.date.issued2013-01-17
dc.description.abstractObjective: Immune thrombocytopenia (ITP) is a common bleeding disorder in childhood, characterized by isolated thrombocytopenia. The International Working Group (IWG) on ITP recently published a consensus report about the standardization of terminology, definitions, and outcome criteria in ITP to overcome the difficulties in these areas. Materials and Methods: The records of patients were retrospectively collected from January 2000 to December 2009 to evaluate the data of children with ITP by using the new definitions of the IWG. Results: The data of 201 children were included in the study. The median follow-up period was 22 months (range: 12-131 months). The median age and platelet count at presentation were 69 months (range: 7-208 months) and 19x10(9)/L (range: 1x10(9)/L to 93x10(9)/L), respectively. We found 2 risk factors for chronic course of ITP: female sex (OR=2.55, CI=1.31-4.95) and age being more than 10 years (OR=3.0, CI=1.5-5.98). Life-threatening bleeding occurred in 5% (n=9) of the patients. Splenectomy was required in 7 (3%) cases. When we excluded 2 splenectomized cases, complete remission at 1 year was achieved in 70% (n=139/199). The disease was resolved in 9 more children between 12 and 90 months. Conclusion: Female sex and age above 10 years old significantly influenced chronicity. Therefore, long-term follow-up is necessary in these children.
dc.description.abstractGereç ve Yöntemler: ITP’li hastalarımıza ait kayıtlar Ocak 2000’den Kasım 2009’a kadar, geriye yönelik olarak, IWG’nin yeni kriterleri kullanılarak değerlendirilmek üzere toplandı. Bulgular: İki yüz bir çocuğun verileri çalışmaya dahil edildi. Ortanca takip süresi 22 ay (12-131 ay) idi. Başvuru anında ortanca yaş ve trombosit sayısı, sırası ile 69 ay (7-208 ay) ve 19x109/L (1-93x109/L) idi. Hastalığın kronikleşmesi açısından iki risk faktörü saptadık: Kız cinsiyet (OR=2,55, CI=1,31-4,95) ve yaşın 10’dan büyük olması (OR=3,0, CI=1,5-5,98). Hayatı tehdit edici kanama, hastaların 5%’inde (n=9) görüldü. Splenektomi yapılması,7 hastada (3%) gerekti. İlk bir yılda splenektomi yapılan 2 hasta göz ardı edildiğinde, tam remisyon (CR) 70% (n=139/199) hastada görüldü. Hastalık, kronik ITP’li olguların 9’unda (%15; 9/60) daha tanıdan itibaren12 ile 90 ay içerisinde düzeldi. Sonuç: Kız cinsiyet ve yaşın 10’dan büyük olması, kronikleşmeyi belirgin olarak etkiledi. Ancak bu çocuklarda uzun sureli takip gereklidir
dc.identifier.citationSezgin, M. E. vd. (2014). "Childhood immune thrombocytopenia: Long-term follow-up data evaluated by the criteria of the international working group on immune thrombocytopenic purpura". Turkish Journal of Hematology, 31(1), 32-39.
dc.identifier.endpage39
dc.identifier.issn1300-7777
dc.identifier.issn1308-5263
dc.identifier.issue1
dc.identifier.pubmed24764727
dc.identifier.scopus2-s2.0-84905918527
dc.identifier.startpage32
dc.identifier.urihttps://doi.org/10.4274/Tjh.2012.0049
dc.identifier.urihttps://jag.journalagent.com/tjh/pdfs/TJH_31_1_32_39.pdf
dc.identifier.urihttp://hdl.handle.net/11452/33090
dc.identifier.volume31
dc.identifier.wos000347435400005
dc.indexed.scopusScopus
dc.indexed.trdizinTrDizin
dc.indexed.wosSCIE
dc.language.isoen
dc.publisherGalenos Yayıncılık
dc.relation.journalTurkish Journal of Hematology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectChildren
dc.subjectThrombocytopenia
dc.subjectLong-term survival
dc.subjectNatural-history
dc.subjectClinical characteristics
dc.subjectManagement
dc.subjectChildren
dc.subjectSplenectomy
dc.subjectItp
dc.subjectDiagnosis
dc.subjectHematology
dc.subjectTrombositopeni
dc.subjectÇocuk
dc.subjectUzun dönem takip
dc.subject.emtreeAdolescent
dc.subject.emtreeArticle
dc.subject.emtreeChild
dc.subject.emtreeChildhood disease
dc.subject.emtreeChildhood immune thrombocytopenia
dc.subject.emtreeChronicity
dc.subject.emtreeControlled study
dc.subject.emtreeCoombs test
dc.subject.emtreeFemale
dc.subject.emtreeFollow up
dc.subject.emtreeHepatitis b rapid test
dc.subject.emtreeHepatitis c rapid test
dc.subject.emtreeHuman
dc.subject.emtreeIdiopathic thrombocytopenic purpura
dc.subject.emtreeInfant
dc.subject.emtreeLong term survival
dc.subject.emtreeMajor clinical study
dc.subject.emtreeMale
dc.subject.emtreeMedical record review
dc.subject.emtreeMucosal bleeding
dc.subject.emtreeRetrospective study
dc.subject.emtreeSplenectomy
dc.subject.emtreeThrombocyte count
dc.subject.emtreeThrombocytopenia
dc.subject.emtreeTreatment outcome
dc.subject.emtreeImmunoglobulin g
dc.subject.emtreePrednisone
dc.subject.scopusIdiopathic Thrombocytopenic Purpura; Romiplostim; Thrombocytopenia
dc.subject.wosHematology
dc.titleChildhood immune thrombocytopenia: Long-term follow-up data evaluated by the criteria of the international working group on immune thrombocytopenic purpura
dc.title.alternativeÇocukluk Çağında İmmun Trombositopeni: Uluslararası İmmun Trombositopeni Çalışma Grubunun Kriterlerine Göre Uzun İzlem Verilerinin Değerlendirilmesi
dc.typeArticle
dc.wos.quartileQ4
dc.wos.quartileQ4
dspace.entity.typePublication
local.contributor.departmentTıp Fakültesi/Pediatrik Hematoloji Ana Bilim Dalı
local.indexed.atPubMed
local.indexed.atWOS
local.indexed.atScopus

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Evim_vd_2014.pdf
Size:
157.39 KB
Format:
Adobe Portable Document Format
Description:

License bundle

Now showing 1 - 1 of 1
Placeholder
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: